» Articles » PMID: 35866114

Evaluation of Epidermal Growth Factor Receptor Gene Mutations in an Iranian Population with Non-Small Cell Lung Carcinoma

Overview
Date 2022 Jul 22
PMID 35866114
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Mutations of the epidermal growth factor receptor () gene, predominantly in exons 18-21, have been highlighted to function as the crucial predictors of the response rate of patients with non-small cell lung cancer (NSCLC) to tyrosine kinase inhibitors (TKIs).

Methods: This study was performed at Tehran University of Medical Sciences. Data and information were retrospectively collected from the period between Dec 2010 and Apr 2014. Exons 18 to 21 of the were analyzed for any potential mutation by PCR, accompanied by DNA sequencing on 160 with pathological confirmation of NSCLC.

Results: Demographically, the male to female ratio was approximately 2:1, and a substantial difference in age between sexes was not observed (=0.065), but a noticeable difference was found in the smoking variable, where 77.8% of males were smokers compared to 17.3% of women (odds ratio (OR) (95% CI) = 16.72 (7.15-39.11)). We found a frequency of 10.63% (17/160) for mutations found in exons 19 and 21, nonetheless, no mutations in exon 18 and exon 20 were observed. The most frequently observed mutations were c.2235_2249, del and c.2240_2257, del in exon 19 and p. L858R in exon 21. The c.2253A>G was found as a novel mutation that was the rarest mutation detected in this work. Interestingly, a remarkable negative association was revealed between smoking and mutation rates in NSCLC patients (OR (95% CI) = 0.13 (0.04-0.46).

Conclusion: The occurrence of mutations is largely varied among the different states of Iran, probably due to variations in ethnicity, smoking rate, and sex ratio of participants.

Citing Articles

Dual-probe ligation without PCR for fluorescent sandwich assay of EGFR nucleotide variants in magnetic gene capture platform.

Kou H, Lin K, Sebuyoya R, Chueh K, Cheng C, Wang C Mikrochim Acta. 2023; 190(9):375.

PMID: 37653003 DOI: 10.1007/s00604-023-05950-5.

References
1.
Howlader N, Forjaz G, Mooradian M, Meza R, Kong C, Cronin K . The Effect of Advances in Lung-Cancer Treatment on Population Mortality. N Engl J Med. 2020; 383(7):640-649. PMC: 8577315. DOI: 10.1056/NEJMoa1916623. View

2.
Zimmer S, Kahl P, Buhl T, Steiner S, Wardelmann E, Merkelbach-Bruse S . Epidermal growth factor receptor mutations in non-small cell lung cancer influence downstream Akt, MAPK and Stat3 signaling. J Cancer Res Clin Oncol. 2008; 135(5):723-30. DOI: 10.1007/s00432-008-0509-9. View

3.
Rajai N, Ghanbari A, Yoosefi M, Mohebi F, Mohajer B, Sheidaei A . National and subnational trends in incidence and mortality of lung cancer in Iran from 1990 to 2016. Asia Pac J Clin Oncol. 2020; 16(3):129-136. DOI: 10.1111/ajco.13303. View

4.
Melosky B . Review of EGFR TKIs in Metastatic NSCLC, Including Ongoing Trials. Front Oncol. 2014; 4:244. PMC: 4164005. DOI: 10.3389/fonc.2014.00244. View

5.
Weir H, Thompson T, Soman A, Moller B, Leadbetter S . The past, present, and future of cancer incidence in the United States: 1975 through 2020. Cancer. 2015; 121(11):1827-37. PMC: 4507799. DOI: 10.1002/cncr.29258. View